(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Most loved Road Food: Which One Prevails upon You? - 2Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- 3Want to make America healthy again? Stop fueling climate change
- 4Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
- 5The most effective method to Succeed in Your Web based Advertising Degree: Procedures for Progress
- Pat Finn, actor from 'The Middle,' dies at 60 after bladder cancer diagnosis
- Vote In favor of Your Favored Kind Of Tea
- It's been 20 years since MTV's golden couple split. These producers saw it all unravel.
- Flu cases spiking this holiday season, CDC data shows
- Step by step instructions to Keep up with Ideal Oral Cleanliness at Home
- New trailer for 'Bridgerton' Season 4 teases Benedict's love story: Watch it here
- Cuba fights to contain spread of mosquito-borne chikungunya virus
- Ancient Egyptian pharaoh's boat is being reassembled in public at the Grand Egyptian Museum
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
